340B Insight provides members and supporters of 340B Health with timely updates and discussions about the 340B drug pricing program. The podcast helps listeners stay current with and learn more about 340B to help them serve their patients and communities and remain compliant. We publish new episodes twice a month, with news reports and in-depth interviews with leading health care practitioners, policy and legal experts, public policymakers, and our expert staff.
340B Insight
Claim This Podcastby 340B Health
4.9(26 reviews)
138 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
77
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality89
Social0
YouTube76
Engagement85
Podcast Overview
340B Insight provides members and supporters of 340B Health with timely updates and discussions about the 340B drug pricing program. The podcast helps listeners stay current with and learn more about 340B to help them serve their patients and communities and remain compliant. We publish new episodes twice a month, with news reports and in-depth interviews with leading health care practitioners, policy and legal experts, public policymakers, and our expert staff.
Language
🇺🇲
Publishing Since
5/4/2020
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
77
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality89
Social0
YouTube76
Engagement85
10
Excellent Areas
0
Good Performance
9
Growth Opportunities
excellent
Episode Length
20 minutes
Performing excellently!
needs improvement
Publishing Consistency
Every 16 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
3 verified contact emails on file for 340B Insight
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 26, 2026
How To Calculate How the IRA Will Affect 340B in 2027
340B Vice President of Pharmacy Services and Education Steven Miller explains how hospitals can project the Inflation Reduction Act's impact on 340B savings and budgets for 2027.
May 11, 2026
How To Navigate a Drug Company’s Good-Faith Inquiry
<p>Drug companies often initiate good-faith inquiries of covered entities (CEs) to learn more about certain purchase patterns or volumes, but how should hospitals navigate these requests? Bibi Wishart, director of pharmacy at Atrium Health, describes what she’s learned being on the receiving end of these inquiries.</p><p><br></p><p><strong>Why Do Good-Faith Inquiries Happen?</strong></p><p>Bibi says the recent rise in good-faith inquiries is tied in part to drug companies gaining access to more varied data sources and expressing a goal of ensuring the information they collect is in line with what they are expecting. She says a variety of different factors could trigger this type of inquiry, including new providers purchasing certain drugs, concerns about duplicate discounts, or confusion around whether a drug is being used in an inpatient or outpatient setting. Hospitals are very complicated, so responding to an inquiry often can be more about educating drug companies about how hospitals dispense drugs.</p><p><strong><br>How Should a Hospital Respond?</strong></p><p><br></p><p>If her hospital receives a communication from a drug company through its authorized official and primary contact, Bibi says she prefers to respond within one or two business days just to confirm she has received the inquiry. She says that while it may take several days or weeks to respond with the requested data, that initial response establishes a cooperative tone and ultimately might prevent escalation to a formal audit process. That also gives the 340B team time to pull in the correct departments and hospital data to provide a full response.</p><p><br></p><p><strong>Ways To Prevent the Need for Inquiries</strong></p><p><br></p><p>Due to the sheer complexity of dispensing drugs — including reconciling data feeds from third-party administrators, vendors, and electronic medical records — regular internal audits are one of the best ways to identify discrepancies before drugmakers launch inquiries about them. Bibi recommends using internal auditing to catch these issues and having clear procedures in place for how to resolve any potential errors.</p>
April 13, 2026
The Rebate Debate and Other “Fast and Furious” 340B Developments
<p>340B lately has had a news cycle that seems to change by the hour, and 340B Health President and CEO Maureen Testoni joins us to break down some of the biggest news happening in Washington, D.C., and in courthouses around the country.</p><p><br></p><p><strong>HRSA Seeks Feedback on Reviving Rebates </strong></p><p><br></p><p>After courts halted the rebate pilot that was set to go into effect in January, Maureen notes that the Health Resources & Services Administration is seeking more information on a possible revival of its rebate plans. Hospitals are responding with their objections, as are lawmakers on Capitol Hill. Nearly 100 members of the House of Representatives wrote a letter to the committee in charge of funding HRSA urging it to block federal spending for any HRSA rebate model.</p><p><br></p><p><strong>Huge Rulings on the GPO Prohibition, Child Site Registration</strong></p><p>The past several months have seen big 340B rulings from federal courts. One decision vacated HRSA guidance that had blocked certain 340B hospitals’ use of GPOs for their initial drug inventory, finding that HRSA failed to properly explain the reasons for that restriction. The other decision found that HRSA similarly failed to explain a rationale for restricting 340B eligibility for child sites for up to 23 months after the sites come online. Maureen notes that HRSA could appeal the rulings or seek to issue new guidance.</p><p><br></p><p><strong>Federal Government Weighs in on State Contract Pharmacy Lawsuits</strong></p><p><br></p><p>For the first time, the federal government has filed briefs in support of drug companies in several lawsuits over state contract pharmacy protection laws. In these briefs, Maureen says the government effectively is telling judges it does not believe states have the right to protect contract pharmacy because federal 340B law preempts such actions. With the federal government weighing in on the matter and a recent split among appeals courts over the issue of preemption, it is possible this issue might be appealed at some point to the U.S. Supreme Court.</p><p><br></p><p><strong>Resources</strong></p><ol><li><a href="https://www.340bhealth.org/members/member-tools/member-news/use-our-letter-template-today-to-oppose-development-of-a-new-340b-rebate-program/">Use Our Letter Template Today To Oppose Development of a New 340B Rebate Program</a></li><li><a href="https://www.340bhealth.org/members/member-tools/member-news/bulletin-issue-march-31-2026/nearly-100-L/">Nearly 100 Members of Congress Urge Funding Block for 340B Rebate Model</a></li><li><a href="https://www.340bhealth.org/members/member-tools/member-news/bulletin-issue-march-31-2026/please-help-R/">Please Help Advocate for Enforcement Actions Against Drugmakers’ In-House Claims Data Demands</a></li><li><a href="https://www.340bhealth.org/members/member-tools/member-news/federal-court-vacates-hrsas-2013-gpo-prohibition-policy/">Federal Court Vacates HRSA’s 2013 GPO Prohibition Policy</a></li><li><a href="https://www.340bhealth.org/members/member-tools/member-news/federal-court-decides-hrsa-child-site-eligibility-restrictions-are-unlawful/">Federal Court Decides HRSA Child Site Eligibility Restrictions Are Unlawful</a></li><li><a href="https://www.340bhealth.org/members/member-tools/member-news/federal-government-backs-drug-companies-in-litigation-over-state-contract-pharmacy-laws/">Federal Government Backs Drug Companies in Litigation Over State Contract Pharmacy Laws</a></li><li><a href="https://www.340bhealth.org/members/member-tools/member-news/appeals-court-blocks-west-virginia-340b-contract-pharmacy-law-creating-potential-split-with-other-circuits/">Appeals Court Blocks West Virginia 340B Contract Pharmacy Law, Creating Potential Split with Other Circuits</a></li><li><a href="https://www.340bhealth.org/members/advocacy-tools/impact-profiles/profile-page/">340B Health Impact Profile Guidebook and Template</a></li></ol>
138 total episodes available with 1 transcripts
Recent guests on 340B Insight
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Steven Miller
Guest
Angela Campitelli
Guest
Amanda Nagrotsky
Guest
Adam Porath
Guest
Similar Podcasts
Discover related shows you might enjoy
340B Unscripted
SpendMend Pharmacy
Inside 340B Report
340B Report
340B 360
340B Report
340Banter Podcast
FQHC 340B Compliance
340B Pulse
NorthArcHealth
The Mel Robbins Podcast
Mel Robbins
Pharmacy Innovators Podcast
Visante Consulting
Up First
NPR
Good Hang with Amy Poehler
The Ringer
The Ramsey Show
Ramsey Network
Stuff You Should Know
iHeartPodcasts
Call Her Daddy
Alex Cooper
SmartLess
Jason Bateman, Sean Hayes, Will Arnett
Crime Junkie
Audiochuck
The Daily
The New York Times
Deep-dive analytics for 340B Insight
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is 340B Insight?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.